key: cord-1045184-ay7u4y7a
authors: Feng, Jingjing; Shao, Mi; Hu, Yongxian; Huang, He
title: Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy
date: 2022-01-28
journal: Bone Marrow Transplant
DOI: 10.1038/s41409-022-01562-4
sha: 625e6b9a18c917a906c90cb7674d145e21127149
doc_id: 1045184
cord_uid: ay7u4y7a

nan

where the mean lowest systolic blood pressure was 80 mm/Hg and the mean lowest diastolic blood pressure was 48 mm/Hg. And the average duration of hypotension was 3.5 days. Moreover, the lowest SpO2 level was lower in CLS patients than in non-CLS patients (87.3% vs. 95.6%, p = 0.0028). For treatment, 7 (63.6%) CLS patients used vasopressor and 10(90.9%) patients used diuretics. Half of the non-CLS patients received gamma globulin infusion while more than 90% of the CLS patients received it.

In Fig. 1h , the course of disease of the 11 CLS patients in this study was shown as a swimmer plot. It is noted that patient 10 had two periods of CLS, with the first one starting at day 2 and ending at day 11 and the second one starting at day 20 and ending at day 39.

The first fever post-CAR-T infusion occurred at an average of 1.2 days for CLS patients, which is earlier than the 3.4 days for non-CLS patients (p = 0.0206). Cytokines associated with the severity of CRS were analyzed in this study. The peak concentration of IL-6 in CLS patients was much higher than that in non-CLS patients (9059 vs. 1829 pg/ml, p = 0.001), which is consistent with the well-recognized concept of IL-6 as an indicator of CRS, while the number of days to reach peak IL-6 was not statistically different. The peak IFN-γ in CLS patients was more than 4 times higher than that in non-CLS patients(1400 vs. 345 pg/ml, p = 0.0015). As an important CRS indicator, both CLS and non-CLS patients shared similar baseline ferritin pre-CAR-T, while the peak level of ferritin was much higher in CLS patients (23340 vs. 8846 pg/ml, p = 0.0244). Although the number of days to reach peak ferritin post-CAR-T for CLS patients was shorter than that for non-CLS patients, it did not reach statistical significance. It is important to notice that CLS patients had lower levels of serum total protein (TP, 43.8 vs 53.0 g/L, p = 0.0006) and serum albumin (ALB, 27.4vs 33.9 g/L, p = 0.0015), while hemoglobin concentrations showed no difference. Other cytokines and laboratory indexes including peak levels of IL-10, peak BNP, number of days to peak BNP, peak c-reactive protein and number of days to reach it showed no significant difference. (Fig. 1b-f ).

CLS could be regarded as a syndrome of severe CRS. More than half patients without CLS had 0-2 grade CRS and the remaining 17.2% patients had 3-4 grade CRS. In this study, we found that patients who suffered from CLS all developed 3-4 grade CRS, and patients with high grade of CRS seem to have a greater possibility to develop CLS (Fig. 1g) . Patients with CLS develop their first fever post-CAR-T infusion earlier than patients without CLS. (Fig. 1a ) For laboratory markers, higher peak IL-6 level, peak IFN-γ level, peak ferritin level and lower serum albumin level, total serum protein level after CAR-T infusion are potential markers to develop CLS, although this report is limited by a small sample size.

CLS includes idiopathic systemic CLS and secondary CLS, characterized by leakage of fluid and macromolecules into tissues. There are other causes of secondary CLS such as COVID-19 infection [7] [8] [9] [10] . Post-CAR-T CLS is a complication characterized by severe hypotension, hypoalbuminemia, and hemoconcentration flare-ups, with severe disruption of the vascular endothelium during CLS episodes, resulting in plasma and protein leakage into the interstitial space. The goal of current therapy is to control CRS, reduce inflammatory mediator activation, prevent further capillary leakage, restore blood volume, improve circulatory function, maintain oxygen supply.

The IL-6 receptor antagonist tocilizumab is an important drug for the control of CRS in CAR-T therapy and has not been found to impair the efficacy of CAR-T therapy, so it is possible to control CRS by it and effectively suppress secondary CLS. Steroids can inhibit the inflammatory reaction by inhibiting arachidonic acid metabolism and reducing lysosomal enzyme production, controlling the severity of CRS and improving capillary permeability [11] . At the same time, the application of steroids in CAR-T therapy is controversial [12, 13] , therefore further research is needed to find a balance of steroids use that controls CLS while preserving CAR-T killing effects. Previous studies have shown that IVIG is an effective treatment for systematic CLS [14] . Some reports of secondary CLS suggest that the earlier the IVIG is used the better the treatment may be [15, 16] . However, further studies are needed. 

Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia

Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery

Cardiac profile of chimeric antigen receptor T cell therapy in children: a single-institution experience

ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

Systemic capillary leak syndrome secondary to coronavirus disease 2019

SARS-CoV-2-induces acute and refractory relapse of systemic capillary leak syndrome (Clarkson's disease)

Clarkson's disease episode or secondary systemic capillary leak-syndrome: that is the question! Chest

COVID-19: The key role of pulmonary capillary leakage. An observational cohort study

Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia

High-dose intravenous immunoglobulin therapy for systemic capillary leak syndrome (Clarkson disease)

Antiphospholipids syndrome complicated by a systemic capillary leak-like syndrome treated with steroids and intravenous immunoglobulins: a case report

Capillary leak leading to shock in Kawasaki disease without myocardial dysfunction

JF collected the data and designed and write the article. MS collected the data. YH and HH designed the research and reviewed the article.

The authors declare no competing interests.

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41409-022-01562-4.Correspondence and requests for materials should be addressed to Yongxian Hu or He Huang.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Notation of prior abstract publication/presentation Selected data were presented in abstract form at the 2018 American Society of Hematology meeting